# Jeffrey S. Weber

Source: https://onco.cc/people/jeffrey-weber/  
OnCo record `jeffrey-weber` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 238, which made adjuvant nivolumab standard after melanoma surgery, and co-led the mRNA vaccine trial KEYNOTE-942.

## Summary

Jeffrey Weber was principal investigator of CheckMate 238, which showed adjuvant nivolumab beats ipilimumab in resected stage III-IV melanoma with far less toxicity, and of KEYNOTE-942, the randomised trial showing the individualised mRNA neoantigen vaccine mRNA-4157 plus pembrolizumab reduces recurrence versus pembrolizumab alone. He has led immunotherapy development since the interleukin-2 era and directs melanoma research at NYU.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: melanoma; adjuvant; vaccine
- Role: Deputy Director, NYU Langone Perlmutter Cancer Center; Professor of Medicine
- Specialisms: Melanoma; Adjuvant immunotherapy; Cancer vaccines; Tumour immunology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20JS%5BAuthor%5D%20melanoma%20adjuvant

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Stage III melanoma (after surgery)](https://onco.cc/cancers/stage-iii-melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Laura and Isaac Perlmutter Cancer Center at NYU Langone Health](https://onco.cc/institutions/nyu-perlmutter/)
- trials: [CheckMate 238](https://onco.cc/trials/checkmate-238/), [CheckMate 915](https://onco.cc/trials/checkmate-915/), [INTerpath-001 (V940-001)](https://onco.cc/trials/interpath-001/)
- key papers: [KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery](https://onco.cc/key-papers/paper-keynote-942-lancet-2024/)

---
JSON: https://onco.cc/api/v1/entities/jeffrey-weber.json